Imiquimod

DMSO : 3.28 mg/mL (ultrasonic; warming; adjust pH to 7 with 1 M HCl; heat to 60°C) |H2O : 2.64 mg/mL (ultrasonic; adjust pH to 2 with HCl) |Methanol : < 1 mg/mL (ultrasonic; warming; heat to 60°C)

[1]Athina Angelopoulou, et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858.|[2]Aditya K Gupta, et al. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6 (6) :554-60.|[3]Yuji Kan, et al. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86 (19) :10338-46.|[4]Michael P Schön, et al. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126 (6) :1338-47.|[5]Leslie van der Fits, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009, 182, 9.|[6]Ajla Smajlović, et al. Molecular and histopathological profiling of imiquimod induced dermatosis in Swiss Wistar rats: contribution to the rat model for novel anti-psoriasis treatments. Mol Biol Rep. 2021, 48, 5.|[7]Sangseo Kim, et al. Development and Optimization of Imiquimod-Loaded Nanostructured Lipid Carriers Using a Hybrid Design of Experiments Approach. Int J Nanomedicine. 2023.

ACS Appl Bio Mater. 2019 Feb 18;2 (2) :874-883.|Acta Pharm Sin B. 2024 Oct;14 (10) :4360-4377.|Adv Sci (Weinh) . 2024 Jul 17:e2405158.|Am J Respir Cell Mol Biol. 2023 Mar;68 (3) :256-266.|Arch Microbiol. 2025 Oct 6;207 (11) :290.|Biochem Biophys Res Commun. 2024 Apr 16:704:149661.|Biodes Manuf. 2025 May 22.|Biomaterials. 2021 Apr:271:120724.|Biomaterials. 2022 Mar:282:121411.|Cell Commun Signal. 2023 Aug 18;21 (1) :215.|Cell Commun Signal. 2024 Nov 25;22 (1) :565.|Cell Death Dis. 2025 Jan 20;16 (1) :31.|Cell Rep. 2021 Feb 2;34 (5) :108724.|Diam Relat Mater. 2023 May 26, 110058.|Drug Deliv. 2023 Dec;30 (1) :2183814.|EMBO Rep. 2022 Feb 3;23 (2) :e53499.|FASEB J. 2025 Dec 15;39 (23) :e71278.|FEBS Lett. 2021 Oct;595 (19) :2447-2462.|Int Immunopharmacol. 2024 Sep 21;142 (Pt B) :113190.|J Agric Food Chem. 2024 Jan 17;72 (2) :1055-1066.|J Cell Mol Med. 2024 Apr;28 (8) :e18356.|J Control Release. 2023 Sep:361:443-454.|J Ethnopharmacol. 2024 Apr 6:323:117711.|J Inflamm Res. 2025 Mar 20:18:4213-4231.|J Invest Dermatol. 2022 May;142 (5) :1349-1359.e8.|J Nanobiotechnology. 2022 May 14;20 (1) :228.|J Periodontal Res. 2025 Feb 25.|MedComm (2020) . 2022 Mar 4;3 (1) :e120.|Mol Biomed. 2025 Nov 13;6 (1) :108.|Nat Commun. 2016 May 25;7:11724. |Nature. 2025 May;641 (8061) :202-210.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|Oxid Med Cell Longev. 2022 Oct 12:2022:6264474.|Patent. US20240417738A1.|Patent. US20250235403A1.|Pharmaceutics. 2025 Nov 20;17 (11) :1503.|Preprints. 2024 Aug 27.|Research Square Preprint. 2021 Oct.|Research Square Preprint. 2023 Nov 17.|Research Square Print. 2023 Feb 1.|Sci Rep. 2024 Mar 4;14 (1) :5237.|SSRN. 2025 Jul 30.|SSRN. 2025 Jun 24.|Theranostics. 2023 Apr 9;13 (7) :2226-2240.|Tuberculosis. 2025 Oct 14:155:102698.|bioRxiv. 2024 Apr 20.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell Res. 2025 Jun;35 (6) :437-452.|Int J Pharm. 2023 Dec 15:648:123583.|J Nanobiotechnology. 2023 Feb 10;21 (1) :50.|Nat Commun. 2022 Jul 22;13 (1) :4255.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|protocols.io. 2024 Apr 13.|Virulence. 2023 Dec;14 (1) :2223394.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|Pharmacol Res. 2023 Dec:198:107016.